期刊论文详细信息
Journal of Hematology & Oncology
Challenges and new technologies in adoptive cell therapy
Review
Xiaochun Wan1  Guizhong Zhang1  Pengchao Zhang2 
[1] Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, 1068 Xueyuan Avenue, Nanshan District, 518055, Shenzhen, People’s Republic of China;Center for Protein and Cell-based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, 1068 Xueyuan Avenue, Nanshan District, 518055, Shenzhen, People’s Republic of China;University of Chinese Academy of Sciences, 100049, Beijing, People’s Republic of China;
关键词: Adoptive cell therapy;    Chimeric antigen receptor;    T cell receptor;    Cancer therapy;    Gene transduction;   
DOI  :  10.1186/s13045-023-01492-8
 received in 2023-05-29, accepted in 2023-08-04,  发布年份 2023
来源: Springer
PDF
【 摘 要 】

Adoptive cell therapies (ACTs) have existed for decades. From the initial infusion of tumor-infiltrating lymphocytes to the subsequent specific enhanced T cell receptor (TCR)-T and chimeric antigen receptor (CAR)-T cell therapies, many novel strategies for cancer treatment have been developed. Owing to its promising outcomes, CAR-T cell therapy has revolutionized the field of ACTs, particularly for hematologic malignancies. Despite these advances, CAR-T cell therapy still has limitations in both autologous and allogeneic settings, including practicality and toxicity issues. To overcome these challenges, researchers have focused on the application of CAR engineering technology to other types of immune cell engineering. Consequently, several new cell therapies based on CAR technology have been developed, including CAR-NK, CAR-macrophage, CAR-γδT, and CAR-NKT. In this review, we describe the development, advantages, and possible challenges of the aforementioned ACTs and discuss current strategies aimed at maximizing the therapeutic potential of ACTs. We also provide an overview of the various gene transduction strategies employed in immunotherapy given their importance in immune cell engineering. Furthermore, we discuss the possibility that strategies capable of creating a positive feedback immune circuit, as healthy immune systems do, could address the flaw of a single type of ACT, and thus serve as key players in future cancer immunotherapy.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 预 览 】
附件列表
Files Size Format View
RO202309157650752ZK.pdf 8240KB PDF download
Fig. 2 905KB Image download
Fig. 1 902KB Image download
Fig. 1 247KB Image download
Fig. 1 239KB Image download
13690_2023_1163_Article_IEq2.gif 1KB Image download
Fig. 2 691KB Image download
Fig. 6 669KB Image download
MediaObjects/13046_2023_2792_MOESM21_ESM.xlsx 9KB Other download
511KB Image download
Fig. 2 482KB Image download
【 图 表 】

Fig. 2

Fig. 6

Fig. 2

13690_2023_1163_Article_IEq2.gif

Fig. 1

Fig. 1

Fig. 1

Fig. 2

【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  • [28]
  • [29]
  • [30]
  • [31]
  • [32]
  • [33]
  • [34]
  • [35]
  • [36]
  • [37]
  • [38]
  • [39]
  • [40]
  • [41]
  • [42]
  • [43]
  • [44]
  • [45]
  • [46]
  • [47]
  • [48]
  • [49]
  • [50]
  • [51]
  • [52]
  • [53]
  • [54]
  • [55]
  • [56]
  • [57]
  • [58]
  • [59]
  • [60]
  • [61]
  • [62]
  • [63]
  • [64]
  • [65]
  • [66]
  • [67]
  • [68]
  • [69]
  • [70]
  • [71]
  • [72]
  • [73]
  • [74]
  • [75]
  • [76]
  • [77]
  • [78]
  • [79]
  • [80]
  • [81]
  • [82]
  • [83]
  • [84]
  • [85]
  • [86]
  • [87]
  • [88]
  • [89]
  • [90]
  • [91]
  • [92]
  • [93]
  • [94]
  • [95]
  • [96]
  • [97]
  • [98]
  • [99]
  • [100]
  • [101]
  • [102]
  • [103]
  • [104]
  • [105]
  • [106]
  • [107]
  • [108]
  • [109]
  • [110]
  • [111]
  • [112]
  • [113]
  • [114]
  • [115]
  • [116]
  • [117]
  • [118]
  • [119]
  • [120]
  • [121]
  • [122]
  • [123]
  • [124]
  • [125]
  • [126]
  • [127]
  • [128]
  • [129]
  • [130]
  • [131]
  • [132]
  • [133]
  • [134]
  • [135]
  • [136]
  • [137]
  • [138]
  • [139]
  • [140]
  • [141]
  • [142]
  • [143]
  • [144]
  • [145]
  • [146]
  • [147]
  • [148]
  • [149]
  • [150]
  • [151]
  • [152]
  • [153]
  • [154]
  • [155]
  • [156]
  • [157]
  • [158]
  • [159]
  • [160]
  • [161]
  • [162]
  • [163]
  • [164]
  • [165]
  • [166]
  • [167]
  • [168]
  • [169]
  • [170]
  • [171]
  • [172]
  • [173]
  • [174]
  • [175]
  • [176]
  • [177]
  • [178]
  • [179]
  • [180]
  • [181]
  • [182]
  • [183]
  • [184]
  • [185]
  • [186]
  • [187]
  • [188]
  • [189]
  • [190]
  • [191]
  • [192]
  • [193]
  • [194]
  • [195]
  • [196]
  • [197]
  • [198]
  • [199]
  • [200]
  • [201]
  • [202]
  • [203]
  • [204]
  • [205]
  • [206]
  • [207]
  • [208]
  • [209]
  • [210]
  • [211]
  • [212]
  • [213]
  • [214]
  • [215]
  • [216]
  • [217]
  • [218]
  • [219]
  • [220]
  • [221]
  • [222]
  • [223]
  • [224]
  • [225]
  • [226]
  • [227]
  • [228]
  • [229]
  • [230]
  • [231]
  • [232]
  • [233]
  • [234]
  • [235]
  • [236]
  • [237]
  • [238]
  • [239]
  • [240]
  • [241]
  • [242]
  • [243]
  • [244]
  • [245]
  • [246]
  • [247]
  • [248]
  • [249]
  • [250]
  • [251]
  • [252]
  • [253]
  • [254]
  • [255]
  • [256]
  • [257]
  • [258]
  • [259]
  • [260]
  • [261]
  • [262]
  • [263]
  • [264]
  • [265]
  • [266]
  • [267]
  • [268]
  • [269]
  • [270]
  • [271]
  • [272]
  • [273]
  • [274]
  • [275]
  • [276]
  • [277]
  • [278]
  • [279]
  • [280]
  • [281]
  • [282]
  • [283]
  • [284]
  • [285]
  • [286]
  • [287]
  • [288]
  • [289]
  • [290]
  • [291]
  • [292]
  • [293]
  • [294]
  • [295]
  • [296]
  • [297]
  • [298]
  • [299]
  • [300]
  • [301]
  • [302]
  • [303]
  • [304]
  • [305]
  • [306]
  • [307]
  • [308]
  • [309]
  • [310]
  • [311]
  • [312]
  • [313]
  • [314]
  • [315]
  • [316]
  • [317]
  • [318]
  • [319]
  • [320]
  • [321]
  • [322]
  • [323]
  • [324]
  • [325]
  • [326]
  • [327]
  • [328]
  • [329]
  • [330]
  • [331]
  • [332]
  • [333]
  • [334]
  • [335]
  • [336]
  • [337]
  • [338]
  • [339]
  • [340]
  • [341]
  • [342]
  • [343]
  • [344]
  • [345]
  • [346]
  • [347]
  • [348]
  • [349]
  • [350]
  • [351]
  • [352]
  • [353]
  • [354]
  • [355]
  • [356]
  • [357]
  • [358]
  • [359]
  • [360]
  • [361]
  • [362]
  • [363]
  • [364]
  • [365]
  • [366]
  • [367]
  • [368]
  • [369]
  • [370]
  • [371]
  • [372]
  • [373]
  • [374]
  • [375]
  • [376]
  • [377]
  • [378]
  • [379]
  • [380]
  • [381]
  • [382]
  • [383]
  • [384]
  • [385]
  • [386]
  • [387]
  • [388]
  • [389]
  • [390]
  • [391]
  • [392]
  • [393]
  • [394]
  • [395]
  • [396]
  • [397]
  • [398]
  • [399]
  • [400]
  • [401]
  • [402]
  • [403]
  • [404]
  • [405]
  • [406]
  • [407]
  • [408]
  • [409]
  • [410]
  • [411]
  • [412]
  • [413]
  • [414]
  • [415]
  • [416]
  • [417]
  • [418]
  • [419]
  • [420]
  • [421]
  • [422]
  • [423]
  • [424]
  • [425]
  • [426]
  • [427]
  • [428]
  • [429]
  • [430]
  • [431]
  • [432]
  • [433]
  • [434]
  • [435]
  • [436]
  • [437]
  • [438]
  • [439]
  • [440]
  • [441]
  • [442]
  • [443]
  • [444]
  • [445]
  • [446]
  • [447]
  • [448]
  • [449]
  • [450]
  • [451]
  • [452]
  • [453]
  • [454]
  • [455]
  • [456]
  • [457]
  • [458]
  • [459]
  • [460]
  • [461]
  • [462]
  • [463]
  • [464]
  • [465]
  • [466]
  • [467]
  • [468]
  • [469]
  • [470]
  • [471]
  • [472]
  • [473]
  • [474]
  • [475]
  • [476]
  • [477]
  • [478]
  • [479]
  • [480]
  • [481]
  • [482]
  • [483]
  • [484]
  • [485]
  • [486]
  • [487]
  • [488]
  文献评价指标  
  下载次数:5次 浏览次数:2次